Factor VII Antibodies

Santa Cruz Biotechnology offers a broad range of Factor VII monoclonal antibodies to support research in coagulation and hemostasis. Factor VII monoclonal antibodies are compatible with multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Factor VII is a crucial component in the blood coagulation cascade, playing a key role in the initiation of the extrinsic pathway of coagulation. Its activation leads to the conversion of prothrombin to thrombin, ultimately resulting in fibrin formation and clot stabilization. Understanding the function and regulation of Factor VII is essential for elucidating mechanisms of bleeding disorders and developing therapeutic strategies. Factor VII research has significant implications for understanding cardiovascular diseases and developing targeted treatments. Ongoing studies of Factor VII continue to reveal new insights into blood clotting mechanisms and potential therapeutic approaches. Researchers worldwide rely on Factor VII monoclonal antibodies to advance their understanding of coagulation pathways. Santa Cruz Biotechnology monoclonal antibodies enable researchers to make meaningful contributions to the scientific community's understanding of blood coagulation and related disorders.